Claims for Patent: 7,923,564

Summary for Patent: 7,923,564

Title:	Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
Abstract:	Disclosed herein are methods for synthesizing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide. Also disclosed herein is the hemi-tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates.
Inventor(s):	Thygesen; Mikkel Boas (Copenhagen East, DK), Schlienger; Nathalie (Frederiksberg, DK), Tolf; Bo-Ragnar (Malmo, SE), Andersson; Carl-Magnus A. (Hjarup, SE), Blatter; Fritz (Reinach, CH), Berghausen; Jorg (Lorrach, DE)
Assignee:	ACADIA Pharmaceuticals, Inc. (San Diego, CA)
Application Number:	12/795,547
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,923,564
Patent Claims:	1. Crystalline form C of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)ph- enylmethyl)carbamide tartrate of formula IV, ##STR00032## which shows an endothermic signal at 177.degree. C. as measured by differential scanning calorimetry. 2. The crystalline form of claim 1, wherein the endothermic signal at 177.degree. C. has an enthalpy of fusion of about 129 J/g. 3. The crystalline form of claim 1, wherein the endothermic signal at 177.degree. C. is a melting temperature. 4. The crystalline form of claim 1, which results in a weight loss of about 0.9% below 150.degree. C. as measured by thermogravimetric analysis. 5. The crystalline form of claim 1 that has less than 1000 ppm of residual solvent. 6. The crystalline form of claim 1 that has less than 200 ppm of residual solvent.